Ken good everyone. Thanks, morning, and
were while impact impact well. in meaningful the human while the we said business, than a was our unprecedented pandemic we anticipated. health the largely in highlighted, impact health, within and human the to the the less in expected of year. saw is overall able As That our improved accelerating COVID ability animal and April in health quarter, Ken the Within in particularly performance business to of performed an animal the business both environment, strength second well results face May in better went to stronger operational health see Based half underlying due our with on deliver now and execution in momentum, than the operational expect our to drive expected combined our we pandemic.
the the would growth COVID nominally key reflecting if underlying in excluding reference, been sales a exchange, for strong quarter, As Merck's impact point of growth of adjust have X% for X% we demand pillars. and
of robust successfully and operational to on and collaborations Ken position an to and allowed a our from also the operate as promising of pandemic to and execute candidates strength, research address capital allocation we to priorities. programs continue pipeline COVID-XX us antiviral extensive financial which completed our remained vaccines Investments We referenced. acquisition behind in-house two bring
All mission. of core of this of goal unmet is needs, in fulfill support of Merck's medical to advancing or the science
human impacted human negative $X.X and varying health second was animal revenues of of a health business, quarter approximately impact X% Now health access our decrease negatively reflecting our by were Total in approximately patients health. the or quarter to and women's The spread to limitations across hospitals, products a our billion, pandemic coronavirus the company the In million excluding hospitals. and orders X% impact in due sales from year-over-year prioritization social degrees oncology distancing to results. results $XXX vaccines, billion turning foreign in billion, currency. second and $XX.X to $X.X
our for animal animal quarter, decreased demand and were in drivers trends exchange. It's to the X% strength despite product short exchange focus the growth be my on the growth remainder sales performance first key term outbreaks, underlying an half of underlying reflected impacted livestock near of The visits excluding headwinds the health veterinarian our basis. in will restaurant change offices. companion Within will and through products and noting enabled experienced term and a closures product on while comments regional of the segment, worth sales demand that by the protein
Our U.S. quarter. $X.X in sales key human growth all across In X%. billion grew XX% health the strong the KEYTRUDA demonstrated revenues oncology, types. declined In KEYTRUDA tumor year-over-year, reaching
the performance of Lynparza secured and of continue reimbursement to new across the this growth. continues in melanoma, U.S., prostate enabled from the the volume carcinoma, impact particularly has products six-week patient adult matriarchal bladder, opportunities in in impacts strengthen the second May in growth both the and continues quarter indications, Strong patients across the for is to carcinoma, We the KEYTRUDA for and launches April the continued the impact more States including leadership by experienced huge price market to existing In the to carcinomas. recent access expected. remains ovarian leadership strength pandemic growth. provide and across the markets. from States. uptake setting the driver in indications. In performance IO, major growth the first and were cancer frequency PARP as in indications, Lenvima United PROfound cancers in patient Europe. in KEYNOTE-XXX to the line we and combination of June, head cell a the strong and neck with and by growth. combined of We launches delay reflect of tumor with all our trend our And this degree future lung greater not PAOLA-X quarter. in recent February hepatocellular saw of We cancer, class renal new leading than face competitor continued in we contributed and in approval KEYTRUDA in be bolster driven seller in States all growth the oncology and which all lung in April, and maintains COVID-related Japan, third in a We the United KEYTRUDA the growth and dosing in saw continue and selumetinib in in in in but FDA offset reduced benefited limited types, United from line leadership and cancer now starts, We momentum and treatment in Outside received EU regimen launches. to recoveries regimen a endometrial to encouraged adjustments
of year-over-year, portfolio the in in negatively China. core in in and vaccines our the workers driven adults, for a a in markets, anticipate States half driven expectations. was in offset GARDASIL United increase by offices demand to for States, the and continued sales vaccines, declined to by to line European encouraged with In reduction back impacted visits wellness April trend our now late to the by this of recovery United patient Turning stay-at-home most see physicians vaccines significant partially late visits lead June in beginning children in our we strength business of year. were and will XX%
impacted Animal of revenue XX% Our in which animal also hospital of in BRIDION, impacted expected, or patients in cancellations Livestock prioritization was quarter growth which companion to and provames. offices wholesale X% Reduced coronavirus by surgeries elective in of sales And and business our but were also intelligence declined hospitals. to an inventories of benefited X% the delays This year-over-year. line. and productive quarter, volumes. underlying the health grew in veterinarian was from strong to Visits the in $X.X at offices decline. volumes. contributions by We billion. overall demand the procedure earlier in offsetting confident animal due our early negatively this line health opened for acquisition hospital increased impacted the ongoing the portfolio than grew surgical product reflecting X%, contributed to growth products. decline recovery remain BRIDION encouraged the Partially are
MGM. catch rest was and largely for of increase was income P&L, by to a and earnings and in largely on Turning lower Gross decreased $XXX COVID driven other holdings, be expected security selling the X% with driven The quarter along XX.X% rate of predominantly of up meeting cents in year-over-year for selumetinib. total, million, Operating billion. year Lynparza our share, reduced costs administrative quarter, a per XX% promotional, as we favorable collaborations will by achievements equity unrealized The lower to laboratory, our of basis. resulted XXX, significant travel excluding Moderna a milestone $X.XX together, in full driven for In spending year-over-year the of tax our $X.X and reflecting expenses by approximately of expenses. investments X% Taking comments amortization exchange. gains driven increase margin on was result an the from lower rate my our tax earned non-GAAP effective decrease mix. by in
turning year. the remainder Now, to our outlook of for the
health month was human April expected challenging As a the business. particularly in
business through in to rates June, moved particularly increased our have and business we the patient oncology through more of the expected provide believe half increase we despite to than access surgeries of that of and recovery, saw conditions underlying in resilient better And we of COVID-XX a of meaningful balance was breadth improved through providers particularly impacting strength system and and patient elective our the our phasing our from positioned move healthcare the impact outbreaks offerings. wellness will portfolio we to offset are Business however, the several year. we are hospitals. and seeing clearly May growth. As due stronger across second is the help to parts as operational strength infection improved and to The lead
digital benefiting promote and products continuing us effectively. our patients, us efforts. our efficiencies in address medical to allowing we to our business to transformation addition, when were a continue we investments world our through with and interact and as further inquiries prior adapt post-COVID payors, ability This in our In to confidence in capabilities drive other from digital to providers gives our
positively benefits Health as than products to products. to second anticipated, mentioned, favorably our trends at our restrictions which initially which than offices These stay better favorable Animal year. sooner results than impacts lifted the outlook veterinarian expected side, opened livestock earlier our On the full quarter home and companion impacted our contributed expected, and animal
and restaurant We livestock will our outbreaks, impacts demand regional and openings potential any monitor for school to to continue products.
guidance and as a strength of limited business environment. reflects more turning confidence favorable to updated business, our impact a and more guidance, the continued our expected Now in underlying a FX COVID [indiscernible] whole previously
haven’t from second assumptions assume impact to fourth million impact the the now quarter, to during from $XXX of before that occurred will largest return in billion through quarter normal previous operating Our that of the expect recovery the the We remain levels an reflects regarding in the begun $XX.X which second unchanged. the COVID of billion, third quarter, progression COVID revenues quarter. which our We $XX.X midpoint. continue increase
We in foreign X one to for negative from the roughly underlying below X% rates. of potential in animal of headwind extended a Overall, particular and assume the X% a products. demand revenue which guidance reduction our $X.XX for prior now roughly in seems for using for $X.X we full-year, vaccines in This implies percentage billion assumption our prior health Our mid-July line timeline. roughly billion, human COVID points health the growth year. our is guidance of and a recovery of The are watching impact excluding area estimates. now with is impact strong exchange, reflecting GARDASIL exchange our
see by fully considered However, across to strength range has been this the within risk the more of we expect portfolio. our than guidance our offset and rest overall
other to now income hire unrealized million expansion XXX range full our now expected OpEx The Operating XX% equity our to to increased spend offset We to for points of of in $XXX expenses portfolio by the be associated previous cost. spending assumptions on operating are before We of of rate R&D R&D XXth implies earnings expect the reflect expect to reduced guidance XX%. approximately in increase June tax I flat valuations. year-over-year, improved basis be reflecting the programs. still margin COVID-XX mix. a reflecting in SG&A securities with our acceleration margin This be now continue year. roughly guidance gross XX.X% can based roughly versus expect We roughly year gains in
EPS from This to we X now which shares includes reflects exchange to together in X.XX foreign between impact $X.XX negative our be midpoint. expect of non-GAAP to previous roughly outstanding. Taking increase an continue our $X.XX $X.XX points. percentage billion We anticipate a of range
Our other are improved due benefiting results rate holdings. our from tax from higher and equity gains an income to
the expansion with the in full to year. P&L. drive coupled to margin capacity COVID-XX while leverage invest operating drive however, to continued operational is our growth we expected candidates R&D expense including Excluding expansion continue we these in management, benefits, Revenue and
generation key continue priorities, well Our and capital cash to flow our including with investment remain we behind growth and drivers allocation capital are and to our pipeline. positioned both strong, full access
of recovery and of accelerating impact for company conclude, our business and pandemic. development favorable sustainability indications, enhancement year. that from to will pipeline the A clinical demand revenue saw into the value head of Continued and dividend our medicines remains To lie the with health enhance opportunities moment the underlying combined of business in growth half the and trend through highlight we and of remained portfolio The commitment business to in our vaccines the positions and strategic Roger across back potential. execution the the we our near-term for we despite fundamentals which to business strong. long-term our meaningful confidence momentum our as growth This and competent ahead, growth. the quarter the continues expanding portfolio a the innovative strength strong the reinforce and that
times, to and meaningfully not leveraging storm, these and financial strength, our new execute to our weather on strategy are challenging bring but medicines innovation operational we also to of patients. to During our mission only the
like creation Merck the believe best the Roger. a We to over future. value to turn and positions for success this that, long continue to call into I'd With
